Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 4, 2006, Pages 825-838

  Niederwieser, Dietger ^a   Lange, Thoralf ^a   Cross, Michael ^a   Basara, Nadesda ^a   Al Ali, Haifa ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

acute myelogenous leukemia; graft versus host; graft versus leukaemia

Indexed keywords

ALEMTUZUMAB; AMSACRINE; ANTILEUKEMIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD66; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT; THYMOCYTE ANTIBODY; TIOGUANINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; MINIMAL RESIDUAL DISEASE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; WHOLE BODY RADIATION;

AGED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33748879386     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.06.007     Document Type: Review

References (51)

1. Zittoun R.A., Mandelli F., Willemze R., et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in AML. The New England Journal of Medicine 332 4 (1995) 217-223
2. Hiddemann W., Kern W., Schoch C., et al. Management of acute myeloid leukemia in elderly patients. Journal of Clinical Oncology 17 11 (1999) 3569-3576
3. Burnett A., Goldstone A., and Stevens R. Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 351 (1998) 700-708
4. Buchner T., Hiddemann W., Wormann B., et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine. Blood 93 12 (1999) 4116-4124
5. Löwenberg B., Downing J.R., and Burnett A. Acute myeloid leukemia. The New England Journal of Medicine 341 14 (1995) 1051-1062
6. Cahn J.Y., Labopin M., Sierra J., et al. No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. British Journal of Haematology 110 2 (2000) 308-314
7. Anderlini P., Ghaddar H.M., Smith T.L., et al. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 10 6 (1996) 964-969
8. Burnett A.K., Wheatley K., Goldstone A.H., et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology 118 385 (2002) 400
9. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. The New England Journal of Medicine 331 14 (1994) 896-903
10. Grimwalde D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom medical research council AML11 trial. Blood 98 5 (2001) 1312-1320
11. Grimwalde D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML:Analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92 (1998) 2322-2333
12. Leopold L.H., and Willemze R. The treatment of acute myeloid leukemia in first relapse: A comprehensive review of the literature. Leukemia and Lymphoma 43 9 (2002) 1715-1727
13. Leith C.P., Kopecky K.J., Godwin J., et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A southwest oncology group study. Blood 89 9 (1997) 3323-3329
14. Gratwohl A., Baldomero H., Passweg J., et al. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplantation 30 (2002) 813-831
15. Kolb H.-J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 5 (1995) 2041-2050
16. Slavin S., Naparstek E., Nagler A., et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87 6 (1996) 2195-2204
17. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 3 (1998) 756-763
18. Giralt S., Thall P.F., Khouri I., et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97 3 (2001) 631-637
19. Nagler A., Aker M., Or R., et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Experimental Haematology 29 (2001) 362-370
20. Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99 (2002) 1071-1078
21. McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97 (2001) 3390-3400
22. Niederwieser D., Maris M., Shizuru J.A., et al. Low-dose total body irradiation (TBI) and fludarabine follwed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101 (2003) 1620-1629
23. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplantation 33 (2004) 691-696
24. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89 (1997) 3048-3054
25. Bornhäuser M., Storer B., Slattery J., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 3 (2003) 820-826
26. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 2 (2003) 756-762
27. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. The New England Journal of Medicine 300 (1979) 1068-1073
28. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low dose total body irradiation (TBI) based conditioning and hematopoietic cell transplantation from related and unrelated donors. Journal of Clinical Oncology 24 3 (2006) 444-453
29. Kojima R., Kami M., Kanda Y., et al. Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplantation 36 8 (2005) 667-674
30. Alyea E.P., Kim H.T., Ho V., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 4 (2005) 1810-1814
31. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2005)
32. Godwin J.E., Kopecky K.J., Head D.R., et al. A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031). Blood 91 10 (1998) 3607-3615
33. Sayer H.G., Kröger M., Beyer J., et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplantation 31 (2003) 1089-1095
34. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19 (2005) 2304-2312
35. van Besien K., Artz A., Smith S., et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. Journal of Clinical Oncology 23 24 (2005) 5728-5738
36. Hamaki T., Kami M., Kim S.W., et al. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies. Bone Marrow Transplantation 33 (2004) 891-900
37. Gupta V., Daly A., Lipton J.H., et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biology of Bood and Marrow Transplantation 11 (2005) 764-772
38. Corradini P., Zallio F., Mariotti J., et al. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. Journal of Clinical Oncology 23 27 (2005) 6690-6698
39. Ringhoffer M., Blumstein N., Neumaier B., et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. British Journal of Haematology 130 (2005) 604-613
40. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. Journal of Clinical Oncology 23 36 (2005) 9387-9393
41. Schmid C., Schleuning M., Ledderose G., et al. Sequential Regimen of Chemotherapy, Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation, and Prophylactic Donor Lymphocyte Transfusion in High-Risk Acute Myeolid Leukemia and Myelodysplastic Syndrome. Journal of Clinical Oncology 23 24 (2005) 5675-5687
42. Ho A.Y., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104 6 (2004) 1616-1623
43. Martino R., Caballero M.D., Simon J.A.P., et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100 6 (2002) 2243-2245
44. Bertz H., Potthoff K., and Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. Journal of Clinical Oncology 21 8 (2003) 1480-1484
45. Gomez Nunez M., Martino R., Caballero M.D., et al. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial. Bone Marrow Transplantation 33 5 (2004) 477-482
46. Hallemeier C., Girgis M., Blum W., et al. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biology of Bood and Marrow Transplantation 10 (2004) 310-319
47. Claxton D.F., Ehmann C., and Rybka W. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. British Journal Haematology 130 (2005) 256-264
48. Bornhäuser M., Thiede C., Platzbecker U., et al. Dose-reduced Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors in 42 Patients. Clinical Cancer Research 7 (2001) 2254-2262
49. Feinstein L.C., Sandmaier B.M., Hegenbart U., et al. Non-myeloablative allogafting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. British Journal of Haematology 120 (2003) 281-288
50. Taussig D.C., Davies A.J., Cavenagh J.D., et al. Durable remissions of MDS and AML after reduced-intensity allografting. Journal of Clinical Oncology 21 16 (2003) 3060-3065
51. Wong R., Giralt S.A., Martin T., et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102 8 (2003) 3052-3059